BENFOGAMMA® 150 (Benfogamma® 150)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBenzothiamineBenzothiamine
Similar drugsTo uncover
  • BENFOGAMMA® 150
    pills inwards 
    Wörwag Pharma GmbH & Co. KG. KG     Germany
    • Dosage form: & nbspcoated tablets
    Composition:
    One coated tablet contains: .
    active substance - benfotiamine 150 mg,
    Excipients - cellulose microcrystalline 122.0 mg, povidone K-30 8.0 mg, fatty acid glyceride 5.0 mg, silicon dioxide colloid 7.0 mg, carmellose sodium 3.0 mg, talc 10.0 mg;
    composition of the shell: shellac 3.0 mg, sucrose 70.875 mg, calcium carbonate 66.479 mg, talc 41.314 mg, acacia gum 10,155 mg, corn starch 7,340 mg, titanium
    dioxide 10.932 mg, silicon dioxide colloidal 4,404 mg, povidone K-30 6,210 mg,
    macrogol-6000 1.597 mg, glycerol 85% 2.262 mg, polysorbate 80 0,133 mg, wax
    mountain glycol 0,300 mg.
    Description:Round biconvex shiny pills in white.
    Pharmacotherapeutic group:Vitamin
    ATX: & nbsp

    A.11.D.A.03   Benzothiamine

    Pharmacodynamics:

    Benfotiamine fat soluble thiamine derivative. Thiamine turns into an active thiamine pyrophosphate and as a coenzyme is included in the composition pyruvate decarboxylase, alpha-ketoglutarate decarboxylase complexes that participate in the oxidative decarboxylation of pyruvic and alpha-1 ketoglutaric acid; transketolase - an enzyme of the pentose phosphate shunt.

    Pharmacokinetics:

    Absorption is high, throughout the small intestine. Before absorption, it is released from the bound state by digestive enzymes. After 15 minutes it is found in the blood, after 30 minutes - in other tissues. In the blood, the concentration is relatively low, while the plasma circulates predominantly free thiamine, at erythrocytes and leukocytes - its phosphoric esters. Phosphorylation occurs in the liver. The most active phosphoric ester is thiamine diphosphate, which has coenzyme activity. It accumulates mainly in the liver, heart, brain, kidneys, spleen. 1/2 of the total amount is contained in striated muscles and myocardium and about 40% in internal organs. It is excreted through the intestines and kidneys.

    Indications:

    Deficiency B1, confirmed by clinical and biochemical research, developing against the background of:

    - inadequate and malnutrition (beriberi);

    - parenteral nutrition for a long time, hemodialysis;

    - chronic alcoholism (alcoholic cardiomyopathy, Wernicke's encephalopathy, Korsakov's syndrome);

    - increased need for vitamin B1.

    Polineuropathy due to vitamin B1 deficiency.Typical signs of such a deficiency are neurological disorders in the form of neuropathies with sensory disorders (pain, tingling sensation, loss of sensitivity in the upper and lower extremities).

    Contraindications:

    Individual hypersensitivity to the drug, sucrose deficit / isomaltose, fructose intolerance glucose-galactose malabsorption, pregnancy, infancy.

    Pregnancy and lactation:

    Pregnancy is a contraindication for the use of the drug.

    Dosing and Administration:

    For the treatment of vitamin deficiency B1: 1 time per day for 1 tablet.

    For treatment of polyneuropathies caused by vitamin deficiency B1: the initial dose of 1 tablet 2 times a day for 3 weeks, then 1 tablet daily.

    The duration of treatment depends on its effectiveness and is determined by the doctor.

    The tablet is taken without chewing, with a small amount of water.

    Side effects:
    Allergic reactions: angioedema, hives, itching.
    It is reported about isolated cases of violations by gastrointestinal tract: flatulence, diarrhea, constipation, nausea, abdominal pain.
    The causal relationship with the administration of benfotiamine currently does not have sufficient confirmation, and, possibly, is dose-dependent.
    Interaction:

    Thiamine weakens the effect of depolarizing muscle relaxants (suxamethonium iodide , etc.), is inhibited by fluorouracil.

    Ethanol slows the rate of absorption of thiamine after oral administration.

    Special instructions:

    In elderly people, there were no adverse reactions other than those mentioned above.

    It is not recommended to take a double dose of the drug if the previous dose was missed.

    With encephalopathy Wernicke, the administration of thiamine should be preceded by the administration of dextrose.
    Effect on the ability to drive transp. cf. and fur:

    There is no evidence of the effect of the drug on the ability to drive vehicles and mechanisms, applied in therapeutic doses.

    Form release / dosage:

    Coated tablets 150 mg.

    Packaging:

    For 15 tablets coated with a membrane in a blister of polyvinyl chloride film and aluminum foil; 2 or 4 blisters together with instructions for use are placed in a cardboard box.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N012520 / 01
    Date of registration:02.08.2011 / 11.09.2012
    Expiration Date:Unlimited
    The owner of the registration certificate:Wörwag Pharma GmbH & Co. KG. KGWörwag Pharma GmbH & Co. KG. KG Germany
    Manufacturer: & nbsp
    Information update date: & nbsp23.01.2017
    Illustrated instructions
      Instructions
      Up